Results 31 to 40 of about 63,105 (214)

Sub-MICs of Azithromycin Decrease Biofilm Formation of S. suis and Increase Capsular Polysaccharide Content of S. suis

Frontiers in Microbiology, 2016
S. suis (Streptococcus suis) caused serious disease symptoms in humans and pigs. S. suis is able to form thick biofilms and this increases the difficulty of treatment.
Yanbei Yang, Jianqing Chen, Yulin Zhao, Jing-Wen Bai, Wen-Ya Ding, Yonghui Zhou, Xue-Ying Chen, Di Liu, YanHua Li   +8 more
doaj   +1 more source

Effect of a single dose of oral azithromycin on malaria parasitaemia in children: a randomized controlled trial

Malaria Journal, 2021
Background Azithromycin has recently been shown to reduce all-cause childhood mortality in sub-Saharan Africa. One potential mechanism of this effect is via the anti-malarial effect of azithromycin, which may help treat or prevent malaria infection. This
Boubacar Coulibaly, Ali Sié, Clarisse Dah, Mamadou Bountogo, Mamadou Ouattara, Adama Compaoré, Moustapha Nikiema, Jérôme Nankoné Tiansi, Nestor Dembélé Sibiri, Jessica M. Brogdon, Elodie Lebas, Thuy Doan, Travis C. Porco, Thomas M. Lietman, Catherine E. Oldenburg   +14 more
doaj   +1 more source

Synergistic Advanced Oxidation and Physicochemical Treatment Strategies for Antibiotic Removal and Resistance Mitigation in Water

Asia-Pacific Journal of Chemical Engineering, EarlyView.
ABSTRACT The presence of antibiotics in water not only causes environmental pollution but also increases the growth of antibiotic‐resistant bacterial genes, which pose serious threats to human beings and other water residents. Large numbers of people are reportedly affected by the resistant bacterial genes, as many broad‐spectrum antibiotics are not ...
Amir Zada, Shohreh Azizi
wiley   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Periodontal microbiology and microbial etiology of periodontal diseases: Historical concepts and contemporary perspectives

Periodontology 2000, EarlyView., 2023
Abstract This narrative review summarizes the collective knowledge on periodontal microbiology, through a historical timeline that highlights the European contribution in the global field. The etiological concepts on periodontal disease culminate to the ecological plaque hypothesis and its dysbiosis‐centered interpretation.
Georgios N. Belibasakis, Daniel Belstrøm, Sigrun Eick, Ulvi K. Gursoy, Anders Johansson, Eija Könönen   +5 more
wiley   +1 more source

Azithromycin and the Outcome of Treated COVID-19 Patients: A Hospital-Based Study

Journal of Midwifery, 2022
COVID-19 is an infectious disease that has been declared a pandemic. Currently, there is no validated pharmacological treatment for use in COVID-19 disease and is still in the clinical trial stage.
Elly Usman
doaj   +1 more source

A descriptive case series of hepatotoxicity associated with CFTR modulators and possible relevance of pharmacogenetic polymorphisms in cystic fibrosis patients

British Journal of Clinical Pharmacology, EarlyView.
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are widely used in patients with cystic fibrosis and significantly improve respiratory function and quality of life. However, their effectiveness may be limited by liver damage, which sometimes leads to treatment discontinuation, and the mechanisms underlying this remain poorly ...
Clara Laffitte Redondo, Venceslas Bourdin, Abd El Kader Ait Tayeb, Sihem Benaboud, Inès Martins, Caroline Joyau, Myriam Benhamida, Isabelle Sermet‐Gaudelus, Clémence Martin, Pierre Régis Burgel, Céline Verstuyft, Laurent Chouchana, Estelle Ayme‐Dietrich   +12 more
wiley   +1 more source

Europe's contribution to the evaluation of the use of systemic antimicrobials in the treatment of periodontitis

Periodontology 2000, EarlyView., 2023
Abstract This narrative review celebrates Europe's contribution to the current knowledge on systemically administered antimicrobials in periodontal treatment. Periodontitis is the most frequent chronic noncommunicable human disease. It is caused by dysbiotic bacterial biofilms and is commonly treated with subgingival instrumentation.
David Herrera, Arie Jan van Winkelhoff, Paula Matesanz, Katalina Lauwens, Wim Teughels   +4 more
wiley   +1 more source

Advanced nanotherapeutics for combating ocular infections: Rational design, antimicrobial mechanisms, and therapeutic breakthroughs

BMEMat, EarlyView.
Nanomaterials revolutionize ocular infection treatment by enabling targeted drug delivery and enhanced antimicrobial efficacy against resistant pathogens. This review systematically explores their rational design, multimodal mechanisms, and translational potential for next‐generation anti‐infective therapies.
Yujia Liu, Xuetian Wen, Yue Tan, Rui Zeng, Yijuan Zhang, Tong Lin, Lan Gong, Zichao Luo   +7 more
wiley   +1 more source

Supra and subgingival application of antiseptics or antibiotics during periodontal therapy

Periodontology 2000, EarlyView., 2023
Abstract Periodontal diseases (gingivitis and periodontitis) are characterized by inflammatory processes which arise as a result of disruption of the balance in the oral ecosystem. According to the current S3 level clinical practice guidelines, therapy of patients with periodontitis involves a stepwise approach that includes the control of the patient ...
Elena Figuero, Jorge Serrano, Nicole Birgit Arweiler, Thorsten Mathias Auschill, Ali Gürkan, Gülnur Emingil   +5 more
wiley   +1 more source